Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $2.57 billion. The enterprise value is $2.11 billion.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 59.80 million shares outstanding. The number of shares has increased by 20.38% in one year.
| Current Share Class | 59.80M |
| Shares Outstanding | 59.80M |
| Shares Change (YoY) | +20.38% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 3.35% |
| Owned by Institutions (%) | 65.53% |
| Float | 34.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.56 |
| P/TBV Ratio | 5.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.66, with a Debt / Equity ratio of 0.00.
| Current Ratio | 28.66 |
| Quick Ratio | 27.92 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.95% and return on invested capital (ROIC) is -19.43%.
| Return on Equity (ROE) | -26.95% |
| Return on Assets (ROA) | -18.65% |
| Return on Invested Capital (ROIC) | -19.43% |
| Return on Capital Employed (ROCE) | -26.04% |
| Weighted Average Cost of Capital (WACC) | 6.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +136.02% in the last 52 weeks. The beta is 0.49, so ELVN's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +136.02% |
| 50-Day Moving Average | 35.35 |
| 200-Day Moving Average | 24.60 |
| Relative Strength Index (RSI) | 55.60 |
| Average Volume (20 Days) | 1,106,764 |
Short Selling Information
The latest short interest is 5.37 million, so 8.99% of the outstanding shares have been sold short.
| Short Interest | 5.37M |
| Short Previous Month | 6.05M |
| Short % of Shares Out | 8.99% |
| Short % of Float | 15.63% |
| Short Ratio (days to cover) | 3.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -119.66M |
| Pretax Income | -103.69M |
| Net Income | -103.69M |
| EBITDA | -119.40M |
| EBIT | -119.66M |
| Earnings Per Share (EPS) | -$1.83 |
Full Income StatementBalance Sheet
The company has $462.62 million in cash and $399,000 in debt, giving a net cash position of $462.22 million or $7.73 per share.
| Cash & Cash Equivalents | 462.62M |
| Total Debt | 399,000 |
| Net Cash | 462.22M |
| Net Cash Per Share | $7.73 |
| Equity (Book Value) | 459.60M |
| Book Value Per Share | 7.73 |
| Working Capital | 458.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.30 million and capital expenditures -$158,000, giving a free cash flow of -$70.46 million.
| Operating Cash Flow | -70.30M |
| Capital Expenditures | -158,000 |
| Depreciation & Amortization | 263,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -70.46M |
| FCF Per Share | -$1.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |